Tulane StARR Program
Tulane StARR Program
批准号:
10318191
负责人:
JAY K KOLLS
金额:
$30.8万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-01-01 至 2024-12-31
关键词:
AchievementAddressAmericanAreaBasic ScienceCenters of Research ExcellenceChildhoodClinicClinicalClinical MedicineClinical ResearchClinical SciencesClinical TrialsCommunicationDevelopmentDevelopment PlansDiagnosisDiseaseDiverse WorkforceEducational workshopEligibility DeterminationEngineeringEnsureEnvironmentEvaluationExposure toFacultyFellowshipFosteringFundingGoalsGrantHealthHeart DiseasesHematological DiseaseHumanIndividualInstitutional support resourcesInterdisciplinary StudyInternal MedicineKnowledgeLaboratoriesLaboratory ResearchLeadLeadershipLearningLongevityLung diseasesMedicalMedicineMentorsMinorityModelingMolecular GeneticsMonitorNational Heart, Lung, and Blood InstitutePediatricsPhysiciansPopulationPopulation ResearchPositioning AttributePrevention ResearchPrimatesPrincipal InvestigatorProductivityProgram DevelopmentProgram EffectivenessPublic HealthResearchResearch MethodologyResearch Project GrantsResearch SupportResearch TrainingResidenciesResourcesRotationSECTM1 geneScholarshipScienceScientistSelf EfficacySeriesStructureStudentsTeacher Professional DevelopmentTimeTrainingTraining ProgramsTraining SupportTranslatingTranslational ResearchTropical MedicineUnited States National Institutes of HealthUniversitiesWagesWomanWood materialWritingbasecareercareer developmentclinical carecollaborative environmentdesignefficacy evaluationefficacy researchepidemiology studyhealth science researchhuman diseaseimplementation researchimprovedindividual patientinnovationinterestmedical schoolsmedical specialtiesmeetingsnext generationnovel strategiespatient orientedpopulation healthprogramsrecruitresearch and developmentskillssuccesstime use
中文摘要
节目概要
这是杜兰StARR计划的一个新的应用程序,其长期目标是增加数量,
训练有素的,独立的,跨学科的委员会认证的医生科学家从事心脏,
肺和血液疾病的研究。该计划的重点是心脏,肺和血液疾病,因为
这些疾病对人类健康的影响,这些疾病的现有知识差距,
搜索范围,以及杜兰大学这些重点领域的实力。我们成功男人的关键因素-
培训研究和职业发展StARR计划包括:1)靴子营地和教学法,
具体的学者需求; 2)个性化的职业发展培训; 3)StARR医生科学家研讨会
系列; 4)进行中的工作会议; 5)规定的赠款编写和项目管理讲习班; 6)男子-
跨学科研究; 7)负责任的研究培训行为; 8)机构资源;以及9)
StARR学者计划过渡到奖学金培训,K38,K12,K类计划和生物中心,
卓越医学研究(COBRE)创新的方法包括为学者量身定制计划
利用自我效能评估和个人发展计划,并利用网络辅导,
每个学者监督委员会(SOC)的模型,其中包括基础和临床科学方面的专业知识,
和临床护理,以及相关的住院医师项目主任的参与,以确保适当的,
临床和研究轮换的整合。学者们立即接触到研究,并得到指导
尽早建立学术记录,并通过积极参与获得演讲和组织技能
在健康科学研究日,国家科学会议和年度NIH StARR会议上。的
学者们将从Bench(细胞,分子和遗传学)学习尖端的研究方法和技能,
从临床研究和临床试验到人口(流行病学、预防和实施
研究),并在由32个国家领导的实验室/研究小组中开展自己的研究项目,
在一个指导,跨学科的环境,解决NHLBI的优先事项常设NIH资助的导师。
学者的跨学科研究将集中在心脏,肺和血液疾病,并解决总体问题。
主题(生命周期和跨学科研究)。在杜兰大学的大力支持下,
美国内科医学委员会和美国儿科医学委员会的培训,我们建议培训
6名住院StARR学者(3名内科住院医师和3名儿科住院医师; 50%为女性,25%为URM),
个月(在PGY 2,PGY 3和PGY 4的6个月研究块中,80%的精力用于研究)
4年的住院医生计划,同时保持连续性诊所。正在进行的全面评价将
评估并指导改进StARR计划在以下方面的有效性:1)连接研究培训和再培训;
搜索独立性; 2)确保医学和儿科住院医师的董事会资格;以及3)增加
医生科学家的数量和多样性将科学转化为改善人类一生的健康。
英文摘要
Program Summary
This is a new application for the Tulane StARR Program with a long-term goal to increase the number and
diversity of highly trained, independent, interdisciplinary board-certified physician scientists engaging in heart,
lung, and blood diseases research. The program focuses on heart, lung, and blood diseases because of the
impacts of these diseases on human health, the existing knowledge gaps for these diseases across the re-
search spectrum, and the strength of these areas of focus at Tulane. Key components of our successful men-
tored research and career development StARR program include: 1) Boot Camps and didactics tailored to
specific Scholar needs; 2) individualized career development training; 3) StARR Physician Scientists seminar
series; 4) Work-in-Progress sessions; 5) required grant writing and project management workshops; 6) men-
tored interdisciplinary research; 7) responsible conduct in research training; 8) institutional resources; and 9) a
planned transition for StARR Scholars to fellowship training, K38, K12, K-like programs, and Centers of Bio-
medical Research Excellence (COBRE). The innovative approach involves tailoring the program to Scholars
needs using self-efficacy assessment and individual development plans (IDP), and using a network mentoring
model for each Scholar Oversight Committee (SOC) which will include expertise in both basic and clinical sci-
ence and clinical care, as well as participation by the relevant Residency Program Director to ensure appropri-
ate integration of clinical and research rotations. Scholars are immediately exposed to research and are guided
to establish a scholarly track record early, and gain presentation and organization skills by active participation
in the Health Sciences Research days, national scientific meetings, and the annual NIH StARR meeting. The
Scholars will learn cutting-edge research methods and skills from Bench (cellular, molecular, and genetics), to
Bedside (clinical research and clinical trials) to Population (epidemiology, prevention, and implementation
research) and conduct their own research projects in established laboratories/research groups led by 32 out-
standing NIH-funded preceptors in a mentored, interdisciplinary environment that addresses NHLBI priorities.
Scholars' interdisciplinary research will focus on heart, lung, and blood diseases and address overarching
themes (lifespan and interdisciplinary research). With strong institutional support from Tulane and approval of
the training by the American Board of Internal Medicine and American Board of Pediatrics, we propose to train
6 resident StARR Scholars (3 medicine residents and 3 pediatric residents; 50% women and 25% URM) for 18
months (in 6-month Research Blocks in PGY 2, PGY3, and PGY4 with 80% effort dedicated to research) over
the 4-year residency program while maintaining Continuity Clinics. Ongoing and comprehensive evaluation will
assess and guide improvements to the StARR Program's effectiveness in 1) bridging research training and re-
search independence; 2) ensuring board eligibility for medicine and pediatrics residents; and 3) increasing the
number and diversity of physician scientists translating science to improve human health across the lifespan.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tulane StARR Program
-
批准号:10608042
-
项目类别:
-
资助金额:$30.8万
-
财政年份:2021
-
负责人:JAY K KOLLS
-
依托单位:
Immunotherapy of KPC Infection
-
批准号:9981924
-
项目类别:
-
资助金额:$48.64万
-
财政年份:2020
-
负责人:JAY K KOLLS
-
依托单位:
Immunotherapy of KPC Infection
-
批准号:10443796
-
项目类别:
-
资助金额:$48.64万
-
财政年份:2020
-
负责人:JAY K KOLLS
-
依托单位:
Immunotherapy of KPC Infection
-
批准号:10227140
-
项目类别:
-
资助金额:$48.64万
-
财政年份:2020
-
负责人:JAY K KOLLS
-
依托单位:
Immunotherapy of KPC Infection
-
批准号:10671653
-
项目类别:
-
资助金额:$48.64万
-
财政年份:2020
-
负责人:JAY K KOLLS
-
依托单位:
CD4_T-cell_Immunity_in_the_Lung
-
批准号:10321572
-
项目类别:
-
资助金额:$86.92万
-
财政年份:2018
-
负责人:JAY K KOLLS
-
依托单位:
CD4_T-cell_Immunity_in_the_Lung
-
批准号:10559497
-
项目类别:
-
资助金额:$86.92万
-
财政年份:2018
-
负责人:JAY K KOLLS
-
依托单位:
Training in CD4 T-cell Lung Immunity
-
批准号:9804524
-
项目类别:
-
资助金额:$9.37万
-
财政年份:2018
-
负责人:JAY K KOLLS
-
依托单位:
Generation of Novel Human Monoclonals for Lung Disease
-
批准号:9250044
-
项目类别:
-
资助金额:$6.79万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Generation of Novel Human Monoclonals for Lung Disease
-
批准号:9128312
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
-
批准号:10521311
-
项目类别:
-
资助金额:$47.95万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
-
批准号:9210593
-
项目类别:
-
资助金额:$24.87万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
-
批准号:10375091
-
项目类别:
-
资助金额:$51.07万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Th17 Cytokines and Lung Immunity
-
批准号:8990110
-
项目类别:
-
资助金额:$8.62万
-
财政年份:2015
-
负责人:JAY K KOLLS
-
依托单位:
Th17 Cytokines and Lung Immunity
-
批准号:9193101
-
项目类别:
-
资助金额:$26.39万
-
财政年份:2015
-
负责人:JAY K KOLLS
-
依托单位:
Core C RNA Sequencing and Bioinformatics
-
批准号:8853015
-
项目类别:
-
资助金额:$27.58万
-
财政年份:2015
-
负责人:JAY K KOLLS
-
依托单位:
UPITT Rheumatoid Arthritis Combined Center (UPITT RACC)
-
批准号:8932653
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2014
-
负责人:JAY K KOLLS
-
依托单位:
Novel Macrolide Th17 Inhibitors
-
批准号:8130158
-
项目类别:
-
资助金额:$7.89万
-
财政年份:2011
-
负责人:JAY K KOLLS
-
依托单位:
Novel Macrolide Th17 Inhibitors
-
批准号:8255486
-
项目类别:
-
资助金额:$21.74万
-
财政年份:2011
-
负责人:JAY K KOLLS
-
依托单位:
Novel Macrolide Th17 Inhibitors
-
批准号:8389005
-
项目类别:
-
资助金额:$10.49万
-
财政年份:2011
-
负责人:JAY K KOLLS
-
依托单位:
海外基金